Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2026)

Catalyst Pharmaceuticals (CPRX) has 7 years of Deferred Taxes data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 0.65% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 31.11% YoY), and the FY2025 full-year result was $6.8 million, down 27.05% from the prior year.
• Deferred Taxes for Q1 2026 stood at $2.3 million, down from $4.5 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $13.9 million in Q3 2023 and bottomed at -$2.6 million in Q4 2024.
• The 5-year median for Deferred Taxes is $1.6 million (2024), against an average of $1.9 million.
• The widest annual swing landed in 2023, when Deferred Taxes soared 1592.83%; it then tumbled 189.35% in 2024.
• A 5-year view of Deferred Taxes shows it stood at -$1.3 million in 2022, then soared by 31.28% to -$883000.0 in 2023, then sank by 189.35% to -$2.6 million in 2024, then surged by 276.56% to $4.5 million in 2025, then sank by 48.22% to $2.3 million in 2026.
• The last three Deferred Taxes figures came in at $2.3 million (Q1 2026), $4.5 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.

Peer Comparison